Studies have shown oxidized low-density lipoprotein to be associated with the incidence of proliferative retinopathy and other complications of type 1 diabetes mellitus. Because low-risk interventions are available to modify oxidized low-density lipoprotein, it is important to examine the relationships between this factor and the incidence of proliferative retinopathy and of macular edema, 2 important causes of visual impairment in people with type 1 diabetes.
dizing compounds represent part of the normal mechanism of defense against invading microorganisms and malignant cells, and they form during tissue healing and remodeling. Oxidative stress may occur when oxidizing compounds accumulate owing to the tissue's inability to metabolize them. Oxidative stress in persons with type 1 diabetes mellitus has been attributed to hyperglycemia, nonenzymatic protein glycation, and the decreased presence of antioxidants, resulting in less removal of reactive oxygen species. 3 This may lead to the peroxidation of low-density lipoprotein (LDL), which has been hypothesized to cause the death of retinal vessel pericytes, endothelial cells, and retinal cells of Müller, resulting in exacerbation of diabetic retinopathy (DR).
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Few long-term cohort studies have examined the association of serum oxidized LDL (ox-LDL) with the incidence and worsening of DR in persons with diabetes. 4 In our report, we examine relationships of serum ox-LDL level with the incidence of proliferative DR (PDR), the incidence of diabetic macular edema (DME), and the worsening of DR by 2 or more steps in participants with type 1 diabetes in the Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR).
Methods

Study Population
Detailed descriptions of the WESDR cohort, participation statistics, and reasons for nonparticipation have appeared elsewhere. [5] [6] [7] [8] [9] [10] [11] In brief, the WESDR identified 1210 persons with . [5] [6] [7] [8] [9] [10] [11] No stereoscopic fundus photographs were taken at the 2000-2001 examination, and data from that examination were not used in the analyses. No individuals with a history of kidney or pancreas transplant or renal dialysis were included in the analyses. The tenets of the Declaration of Helsinki were followed, and institutional review board approval was obtained from the University of Wisconsin in Madison. Written informed consent was obtained from each participant.
Examination
Pertinent parts of the examination included the measurements of blood pressure, height, and weight and the recording of answers to questions regarding the use of tobacco products and lipid-lowering medications.
Laboratory Procedures
Nonfasting blood samples were collected, processed within 1 hour of collection, and frozen at −80°C beginning at the third examination in 1990-1992 and through 4 follow-up examinations. The ox-LDL level was measured in these samples; thus, the third examination serves as the "baseline" examination for the purposes of this analysis. 
Definitions
Age was defined as the age at the time of each examination. Age at diagnosis of diabetes was defined as the age at the time
At a Glance
• We examined the relationship between the level of oxidized low-density lipoprotein and the incidence of proliferative retinopathy and of macular edema in type 1 diabetes.
• We found an increase in risk for incident proliferative diabetic retinopathy with an increase in the level of oxidized low-density lipoprotein over the preceding period that warrants further investigation. • We did not find evidence that the level of oxidized low-density lipoprotein is associated with the incidence of macular edema independent of other risk factors.
the diagnosis was first recorded by a physician in the participant's medical record or in a hospital record. The duration of diabetes was defined as the period between the age at diagnosis and the age at the specific examination. Systolic and diastolic blood pressures were defined as the average of the 2 measurements taken according to the Hypertension Detection and Follow-up Program protocol.
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A participant was classified as a never smoker if he or she had smoked fewer than 100 cigarettes in his or her lifetime, an ex-smoker if he or she smoked 100 or more cigarettes in his or her lifetime but had stopped smoking before the examination, and a current smoker if he or she had not stopped smoking. Body mass index (BMI) was defined as the participant's weight in kilograms divided by the height in meters squared. Proteinuria was defined as a urine protein concentration of 30 mg/dL or more as measured by Labstix (Ames).
Statistical Methods
While adjusting for duration of diabetes, HbA 1c level, statin use, sex, proteinuria, smoking status, BMI, systolic blood pressure, WESDR visit, and the DR severity level at the time the serum sample of ox-LDL was obtained, we examined the association of the ox-LDL levels at the beginning of 3 periods (1990-1992, 1994-1996, and 2005-2007) with the incidence of PDR, the incidence of DME, and 2 or more steps of worsening of DR at the end of each period (1994) (1995) (1996) (2005) (2006) (2007) The association of an increase in ox-LDL level during the 4-year period between the 1990-1992 and 1994-1996 examinations with the subsequent 11-year incidence of PDR and of DME and the worsening of DR between the 1994-1996 and 2005-2007 examinations was modeled using logistic regression in SAS version 9.1 (SAS Institute). Models were adjusted for sex and duration of diabetes, as well as changes in HbA 1c level, statin use, proteinuria, smoking status, BMI, systolic blood pressure, and DR severity from the beginning to the end of the 4-year period.
Deming regression 16 was used to evaluate the comparability of the ox-LDL levels obtained from the quality-control samples between the first and second batches sent to the laboratory. We found that the ox-LDL levels in the quality-control samples in the first batch were not comparable to those in the second batch (P < .05). Based on these results, we transformed the levels for all the samples in the second batch to be comparable to those in the first batch. The distribution of baseline ox-LDL levels, after the transformation of the samples obtained from participants in the second batch, is presented in eFigure 1 in the Supplement.
Results
Participant Characteristics
There were 813 persons (1886 person-intervals) who participated in the WESDR examinations in 1990-1992, 1994-1996, and/or 2005-2007 . Of the 1886 person-intervals, 322 were excluded because frozen serum samples were unavailable to measure the ox-LDL level; 709 were excluded because the participant was not at risk for any of the outcomes of interest or because there was missing data on DR severity, DME, or PDR status; and 16 were excluded because of missing data on covariates. After these person-intervals were excluded, 428 participants remained eligible, and they contributed 832 personintervals to the analyses (728 person-intervals for worsening of DR and incidence of PDR and 720 person-intervals for incidence of DME). At the baseline WESDR examination, the participants included in the analyses were more likely to be younger and, after adjustment for age and sex, were more likely to have a shorter duration of diabetes, a lower HbA 1c level, a lower ox-LDL level, a lower serum total cholesterol level, and lower systolic blood pressure, and were less likely to have proteinuria, prevalent PDR, or DME compared with those who were excluded ( Table 1) .
Distribution of Oxidized LDL Levels and Associated Risk Factors
The mean (SD) ox-LDL level was 30.0 (8.5) U/L. We found significant inverse trends of age, duration of diabetes, and history of using statins. We found positive associations of HbA 1c level, systolic blood pressure, BMI, presence of proteinuria, and presence of PDR with increasing quartile ranges of ox-LDL level ( Table 2) . The results were similar when the ox-LDL level was treated continuously (data not shown). We did not find any associations of sex, systolic blood pressure, and history of current smoking with ox-LDL levels.
Incidence of PDR and DME and Worsening of DR and 123 contributing to the analyses of the 11-year incidence of DME. At the baseline examination, the participants included in the analyses were more likely to have a shorter duration of diabetes, a lower HbA 1c level, a lower serum total cholesterol level, a lower ox-LDL level, lower systolic blood pressure, and less prevalent proteinuria, PDR, or DME compared with those excluded after adjusting for age and sex ( Table 4) . The distribution of change in ox-LDL level between the baseline and 4-year follow-up examinations is shown in eFigure 2 in the Supplement. Change in ox-LDL level was slightly skewed to the right with a mean (SD) of 1 (7.0) U/L.
Among the 151 participants remaining in our study, DR worsened in 49 of 144 participants at risk (34.0%) by 2 or more steps, 21 of 144 participants at risk (14.6%) developed PDR, and 4 of 123 participants at risk (3.3%) developed DME over the subsequent 11-year period. Adjusting for age and sex, we found that the change in ox-LDL level was marginally associated with the incidence of PDR (odds ratio [OR], 1.63 [95% CI, 0.96-2.76]; P = .07) but not with the incidence of DME (OR, 1.20 [95% CI, 0.47-3.05]; P = .70) or the worsening of DR (OR, 1.40 [95% CI, 0.91-2.14]; P = .12). After further adjustment for change in HbA 1c level, history of statin use, proteinuria, smoking status, BMI, and DR level over the same period, there remained a marginal association of a 77% higher subsequent 11-year incidence of PDR with a 10-U/L increase in the ox-LDL level between the 1990-1992 and 1994-1996 examinations (OR, 1.77 [95% CI, 0.99-3.17]; P = .06) ( Table 5) . Change in ox-LDL level was not associated with the worsening of DR (OR, 1.32 [95% CI, 0.83-2.09]; P = .24) or the incidence of DME (OR, 1.08 [95% CI, 0.44-2.61]; P = .87).
Discussion
In the WESDR, while adjusting for duration of diabetes and other covariates, we found no significant relationships between serum ox-LDL level and the incidence of PDR, incidence of DME, or worsening of DR. To our knowledge, there are no cohort studies that have measured the relationships between change in serum ox-LDL level and the subsequent incidence of PDR and DME and the worsening of DR to which WESDR findings can be compared. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study 17 used a different measure of ox-LDL that is found in immune complexes, which is a result of the formation of autoantibodies due to the activation of the T cells by ox-LDL. In this study, while adjusting for HbA 1c level, LDL level to be related to the incidence of PDR over a 16-year period in persons with no DR at baseline (HR per 1 SD = 2.17 [95% CI, 1.19-3.98]; P = .01) but not in persons with DR at baseline. They hypothesized that a higher serum immune complex ox-LDL level was more likely to have an effect earlier in the course of diabetes, prior to the onset of DR, through its damaging effect on the retinal pericytes, the inducement of leukostasis in the small retinal capillaries, and the stimulation of growth factors-all pathogenetic processes thought to be associated with the incidence of early DR.
Little is known about their potential roles in the pathogenesis of DR, but oxidized lipoproteins have been shown to increase the risk of atherosclerosis by promoting lipid accumulation in macrophages, which induces their transformation into foam cells. It has been shown that ox-LDL may precipitate an autoimmune reaction, producing immune complexes and promoting a proinflammatory environment. 18 Although ox-LDL immune complexes are upstream of ox-LDL, their correlation has been found to be modest but significant (r = 0.313; P < .005). 19 Oxidized LDL and ox-LDL immune complex are 2 different but related exposure variables, similar to LDL and ox-LDL, or to LDL and small LDL. These differences in ox-LDL and the ox-LDL immune complex may involve differences in the early transcriptional responses of genes involved with inflammation, a hypothesized mechanism in the pathogenesis of DR. 20 To our knowledge, there have been no direct comparisons in a cohort of persons with diabetes on the effect of ox-LDL and the ox-LDL immune complex on the risk of the worsening of DR and the incidence of DME or PDR. A beneficial effect of antioxidants (eg, nicanartine, vitamin E, and lipoic acid) on DR lesions in diabetic animals has been found that suggests the possible role played by oxidative stress in the pathogenesis of DR. [21] [22] [23] Although there are many strengths to our study, including the use of similar standardized protocols to assess the incidence of PDR and of DME, there are also limitations. First, serum levels of ox-LDL may not reflect levels of ox-LDL in retinal tissue. It is presumed that the serum ox-LDL levels reflect similar levels of ox-LDL in the retinal tissue, but this may not be the case. Second, the role of oxidative processes cannot be separated from the effects of lipids themselves on the development and progression of retinopathy. Moreover, we do not know whether high lipid levels, irrespective of ox-LDL levels, are causing the changes in eyes that developed PDR. When we replaced ox-LDL with non-high-density lipoprotein cholesterol in the model, we found no evidence of a relationship (R.K., unpublished data, October 16, 2014). We did not find a relationship of serum non-high-density lipoprotein cholesterol to incident PDR. 37 Another limitation is that we do not know whether serum ox-LDL levels remained stable over the long period between being frozen and being measured. Oxidized LDL is stable for at least 3 years if stored at −70°C or below. 38 Selective survival may have affected the results. In the WESDR, while adjusting for other factors such as duration of diabetes and HbA 1c level, we found that persons with PDR with ox-LDL levels in the highest quartile were 8% more likely (HR, 1.08 [95% CI, 1.04-1.13]) to die sooner than persons with ox-LDL levels in the lowest quartile. A lack of power, as indicated by the wide 95% CIs obtained from model results, may have also limited our ability to be confident about finding or not finding associations. Abbreviations: DME, diabetic macular edema; DR, diabetic retinopathy; OR, odds ratio; ox-LDL, oxidized low-density lipoprotein; PDR, proliferative diabetic retinopathy. a Adjusted for duration of diabetes.
b Adjusted for duration of diabetes, sex, and change in glycated hemoglobin A 1c
